Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | CCR4 | P51679 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652134 | 0.88 | CCR5 (0.52) | CCR5CACNA1GDPP4DPP8DPP9 | |
| SCHEMBL19658478 | 0.87 | CCR5 (0.58) | CCR5OPRM1CCR4OPRD1OPRK1 | |
| SCHEMBL13588400 | 0.75 | SIGMAR1 (0.62) | OPRM1HTR2A | |
| SCHEMBL9675809 | 0.75 | OPRM1 (0.51) | CCR5OPRM1CCR4OPRD1OPRK1 | |
| SCHEMBL24726576 | 0.75 | OPRM1 (0.62) | OPRM1OPRD1OPRK1 | |
| SCHEMBL19658477 | 0.74 | CCR5 (0.55) | CCR5KMT2A | |
| SCHEMBL9556728 | 0.74 | CACNA1G (0.54) | OPRM1CACNA1GHTR2AKMT2A | |
| SCHEMBL19652142 | 0.73 | CCR5 (0.41) | CCR5OPRM1OPRD1OPRK1HTR2A | |
| Ammonia Solution, Strong SCHEMBL27785552 | 0.73 | ACHE (0.59) | OPRM1CACNA1G | |
| SCHEMBL17753981 | 0.73 | TAF1 (0.68) | CCR5OPRM1CCR4OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CCR5 1178/4885OPRM1 4350/4885CCR4 1503/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CCR5 1178/4885OPRM1 4350/4885CCR4 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.